<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47071">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125227</url>
  </required_header>
  <id_info>
    <org_study_id>YH14755-102</org_study_id>
    <nct_id>NCT02125227</nct_id>
  </id_info>
  <brief_title>Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, 2-Way Cross-over Study to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Rosuvastatin and Metformin SR and YH14755 and to Investigate the Effect of Food on the Pharmacokinetics of YH14755</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to Compare the Safety and the Pharmacokinetic Characteristics
      of the Co-administration of Rosuvastatin and Metformin SR and YH14755 and to Investigate the
      Effect of Food on the Pharmacokinetics of YH14755 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>AUClast of rosuvastatin and metformin</measure>
    <time_frame>0~48hr, totally 17 points</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of rosuvastatin and metformin</measure>
    <time_frame>0~48hr, totally 17 points</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of rosuvastatin and metformin</measure>
    <time_frame>0~48hr, totally 17 points</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of rosuvastatin and metformin</measure>
    <time_frame>0~48hr, totally 17 points</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUC of rosuvastatin and metformin</measure>
    <time_frame>0~48hr, totally 17 points</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of rosuvastatin and metformin</measure>
    <time_frame>0~48hr, totally 17 points</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1 of Study A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dosing of Rosuvastatin and Metformin 14 days later, single dosing of YH14755</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 of Study A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dosing of YH14755 14 days later, single dosing of Rosuvastatin and Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 of Study B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dosing of YH14755 with fasting state 14 days later, single dosing of YH14755 after having breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 of Study B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dosing of YH14755 after having breakfast 14 days later, single dosing of YH14755 with fasting state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin, Metformin, YH14755</intervention_name>
    <description>single dose</description>
    <arm_group_label>Group 1 of Study A</arm_group_label>
    <arm_group_label>Group 2 of Study A</arm_group_label>
    <other_name>Crestor, GlucodaunOR, YH14755</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH14755</intervention_name>
    <description>single dose</description>
    <arm_group_label>Group 1 of Study B</arm_group_label>
    <arm_group_label>Group 2 of Study B</arm_group_label>
    <other_name>YH14755</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female with a body mass index(BMI) between 18.5 and 25 kg/m2

          2. Who has not suffered from clinically significant disease

          3. Provision of signed written informed consent

        Exclusion Criteria:

          1. History of and clinically significant disease

          2. A history of drug abuse or the presence of positive reactions to drugs that have
             abuse potential in urine screenings for drugs.

          3. Administration of other investigational products within 3 months prior to the first
             dosing.

          4. Administration of herbal medicine within 4 weeks or administration of ethical drugs
             within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior
             to the first dosing of the investigational product (if the investigator (study
             doctor) determines that the person meets other criteria appropriately, the relevant
             person may participate in the study).

          5. Volunteers considered not eligible for the clinical trial by the investigator (study
             doctor) due to reasons including laboratory test results, ECGs, or vital signs.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>min gul kim, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Su Youn Nam, MD, Ph.D</last_name>
    <phone>+82-8-828-0432</phone>
    <email>namsu@yuhan.co.kr</email>
  </overall_contact>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
